Efficacy of CeraVe® Moisturizing Cream on Skin Pruritus in Elderly Patients

Last updated: March 19, 2023
Sponsor: Shanghai Zhongshan Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Rash

Hives (Urticaria)

Skin Wounds

Treatment

N/A

Clinical Study ID

NCT05779150
B2023-004
  • Ages > 60
  • All Genders

Study Summary

The goal of this clinical trial is to evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus. The main questions it aims to answer are:

type of study: clinical trial participant population:in patients with chronic elderly pruritus [question 1] Evaluate the CeraVe® moisturizing cream's efficiency on the improvement of skin barrier in patients with chronic elderly pruritus, including improvements of redness, dryness/squamation, itching, burning, tingling, tightness and other factors.

[question 2] Evaluate the tolerance of CeraVe® Moisturising Cream. [question 3] Evaluate the product experience of patients who were utilizing CeraVe® Moisturising Cream.

This trial utilizing simple randomization, the left and right calves of paticipants were randomly divided into test side(applicating CeraVe® Moisturising Cream ) and control side (applicating Standard Cream)according to random number representation. Grouping results were double-blinded.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patients age≥60 years old(male or female).
  • Clinician evaluates dry pruritus or patient complains of pruritus, which lasts formore than 1 month.
  • Patients informed consent to the purpose and content of the research, willing tocooperate with follow-up observation. Have good communication and understandingskills.
  • Patients are willing to share photos for medical research purpose.

Exclusion

Exclusion Criteria:

  • Patients with bacterial and/or viral infections in the acute phase of skininflammation
  • The affected area is complicated by other skin diseases that may affect the efficacyevaluation
  • Those who are allergic to the ingredients of this product or with allergicconstitution
  • Patients who have severe heart, brain, lung, or liver damage.
  • Those who have received systemic or local antiallergic drug treatment within 2 weeksbefore enrollment of this study.
  • Those who attending other clinical drug trials within 4 weeks before enrollment ofthis study.
  • Patients with a history of alcohol or drug abuse.
  • Patients who are unwilling to sign the informed consent form, and those who areunwilling to cooperate.

Study Design

Total Participants: 50
Study Start date:
February 26, 2023
Estimated Completion Date:
February 03, 2024

Connect with a study center

  • Zhongshan Hospital,Fudan University

    Shanghai, Shanghai 200032
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.